ArticleFrontiers in oncology2022

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.

Rachel Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.